Chang D M, Weinblatt M E, Schur P H
Division of Rheumatology/Immunology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, ROC.
J Rheumatol. 1992 Nov;19(11):1678-82.
The effect of methotrexate (MTX) treatment on patients with rheumatoid arthritis on interleukin 1 (IL-1) was evaluated. Eight patients received a weekly MTX dose of 7.5 mg for 6 weeks; none received concomitant corticosteroids. Peripheral blood was obtained 1 day before and 1 day after their weekly MTX dose at Week 1 and 6, isolated monocytes stimulated ex vivo with 1 mg/ml zymosan for 18 h and IL-1 measured by bioassay. Serum and plasma IL-1 levels were measured by immunoassay. Four patients manifested a sharp decrease in IL-1 production 6 weeks after MTX administration associated with a decrease in the number of painful but not swollen joints. No effect on blood levels was observed. Our results suggest that MTX may affect IL-1 production and IL-1 mediated events in some patients.
评估了甲氨蝶呤（MTX）治疗对类风湿性关节炎患者白细胞介素1（IL-1）的影响。8名患者每周接受7.5毫克MTX治疗，持续6周；均未同时接受皮质类固醇治疗。在第1周和第6周，于每周MTX给药前1天和给药后1天采集外周血，分离单核细胞，用1毫克/毫升酵母聚糖进行体外刺激18小时，并通过生物测定法测量IL-1。通过免疫测定法测量血清和血浆IL-1水平。4名患者在MTX给药6周后IL-1产生急剧下降，同时疼痛关节数量减少，但肿胀关节数量未减少。未观察到对血液水平的影响。我们的结果表明，MTX可能会影响一些患者的IL-1产生和IL-1介导的事件。
